Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.
Penny stocks, under $5 per share, suffer from poor reputation. However, when you get right down to the issue, it’s purely a matter of preference. Most stocks can hide weak fundamentals given the right circumstances, but penny stocks offer a great return value for little investment.
Top Penny Stocks to Buy
No doubt, the risk of penny stocks is higher unless you do your diligence. Leveraging the top platforms for penny stock trading will minimize risk, but these three stocks have already been vetted by the pros in the trading community. If you’re looking for the top penny stocks to buy, the following three are in the advanced bio-medicinal field, without being directly related to COVID-19 vaccine efforts.
Trevi Therapeutics (TRVI)
According to bullish Gary Nachman of the BMO Capital, TRVI is well on its way to demonstrate efficacy with nalbuphine ER. Dubbed Haduvio, this drug is aimed to alleviate neurological conditions varying in severity. This can either be dyskinesia in Parkinson’s patients, chronic pruritus, or chronic cough with patients suffering from idiopathic pulmonary fibrosis (IPF).
Although different at first glance, these conditions all share the common root of the problem in the form of opioid receptors along the central and peripheral nervous systems. As the drug leaves Phase 2b/3 of the so-called PRISM trial, it shows promise for the treatment of a number of symptoms, among which is the suppression of coughing.
Nachman and other Wall Street analysts place the potential growth of Trevi Therapeutics (TRVI) between 142% and 196% going into the next year. With COVID-19 causing more and more people to learn how to trade stocks, Trevi Therapeutics is likely to only see an increase in traction.
Infinity Pharmaceuticals (INFI)
A highly-rated Wall Street analyst from Oppenheimer, Kevin DeGeeter, puts forward INFI. Following the biotech company’s Q2 2020 results, INFI’s prospects are rising. Currently in the middle of two studies, MARIO-275 and MARIO-3, related to treating urothelial cancer, initial clinical tests showed no significant liver toxicity.
The COVID-19 pandemic proved to be a setback, but only temporary. Testing of different effects of dosages in treating urothelial cancer will continue until the end of this year. Therefore, DeGeeter and other Wall Street analysts place INFI at a high growth trajectory between 119% and 203% next year.
OncoSec Medical (ONCS)
We have already addressed the revolutionary plasmid technology in our previous piece on Inovio Pharmaceuticals (INO). As the company name clues you in, OncoSec decided to employ this DNA delivery mechanism in the treatment of cancers. In particular, in developing cancer treatments that are not so devastating to the patient as the chemotherapy.
Wall Street analyst Jason Kolbert, of Dawson James, gives ONCS a high review because of the effectiveness of its proprietary plasmid delivery tech called TAVO – tavokinogene telseplasmid. During the Phase 2 trial, TAVO managed to turn cold skin tumors into hot, making skin cancer easier to treat.
Additionally, in the Phase 2 trial, 41% of patients inflicted with skin cancer responded exceedingly well, achieving the best ORR – best overall objective response rate. Furthermore, 36% of patients reacted with complete responses to TAVO treatment. To round up the good news, patients tolerated the treatment drastically better than established skin cancer treatments.
Lastly, the highly promising TAVO treatments are likely to expand into the treatment of SCCHNCC and TNBC cancers, relating to cancers on the areas of head, neck, and breasts. Cancer is the most difficult type of disease to combat, but ONCS’s methods look promising, placing its shares between 104% and 150% gain into the next year.
What do you think about these top penny stock picks? Are any other penny stocks on your radar? Let us know in the comments section below.